سعر ميباكوفين 100 مجم اس ار 20 كبسولة 2022

Ketoprofen 100 mg sustained-release oral capsules (Mepaco), 20 capsules.

• Symptomatic treatment of chronic inflammatory rheumatism such as rheumatoid arthritis and ankylosing spondylitis.Population: Adults and adolescents over 15 yearsHealth Products Regulatory Authority (HPRA, formerly Irish Medicines Board)
• Symptomatic treatment of osteoarthritis.Population: Adults and adolescents over 15 yearsHealth Products Regulatory Authority (HPRA, formerly Irish Medicines Board)

• Mostly gastrointestinal: peptic ulcer, perforation or GI bleeding (sometimes fatal), nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain; oedema, hypertension and cardiac failure have been reported.International label, same formulation · Health Products Regulatory Authority (HPRA, formerly Irish Medicines Board)

• Hypersensitivity to ketoprofen; history of asthma induced by ketoprofen, other NSAIDs or aspirin.International label, same formulation · Health Products Regulatory Authority (HPRA, formerly Irish Medicines Board)
• History of NSAID-related gastrointestinal bleeding or perforation; active or recurrent peptic ulcer/haemorrhage; active gastrointestinal, cerebrovascular or other bleeding.International label, same formulation · Health Products Regulatory Authority (HPRA, formerly Irish Medicines Board)
• Severe hepatic, renal or heart failure; last trimester of pregnancy.International label, same formulation · Health Products Regulatory Authority (HPRA, formerly Irish Medicines Board)

• Use the lowest effective dose for the shortest duration; avoid combination with other NSAIDs including COX-2 inhibitors.International label, same formulation · Health Products Regulatory Authority (HPRA, formerly Irish Medicines Board)
• Gastrointestinal bleeding, ulceration or perforation may occur, particularly in the elderly; caution with corticosteroids, anticoagulants, SSRIs or antiplatelet agents.International label, same formulation · Health Products Regulatory Authority (HPRA, formerly Irish Medicines Board)
• Some NSAIDs may slightly increase arterial thrombotic risk; careful consideration in uncontrolled hypertension, heart failure, ischaemic heart, peripheral arterial or cerebrovascular disease; monitor renal function in at-risk patients.International label, same formulation · Health Products Regulatory Authority (HPRA, formerly Irish Medicines Board)

• Other NSAIDs (including high-dose salicylates)Combination to be avoided: increased risk of gastrointestinal ulcer and haemorrhage.Health Products Regulatory Authority (HPRA, formerly Irish Medicines Board)
• Oral anticoagulants, heparins, ticlopidineCombination to be avoided: increased bleeding risk; if unavoidable, close clinical and laboratory monitoring.Health Products Regulatory Authority (HPRA, formerly Irish Medicines Board)
• LithiumRaised blood lithium levels, possibly toxic; monitor lithium levels and adjust dose.Health Products Regulatory Authority (HPRA, formerly Irish Medicines Board)

• NSAIDs are excreted in breast milk; avoid during breastfeeding as a precaution.International label, same formulation · Health Products Regulatory Authority (HPRA, formerly Irish Medicines Board)

English text not available for this section.